What this means
A daily dose of this drug will be given for 4 weeks to about 30 people. This is a plan only, so no results exist yet and we cannot tell if it helps.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 65–80 · About 30 people, not yet enrolled
- Where
- 1 site, including Washington
The science
- Registered title
- Study of Healthy Aging and Physical Function With Elamipretide
- Trial ID
- NCT07275424 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Aging, Healthy
- What is tested
- Elamipretide will be supplied as a sterile 5.0 mL single-patient, multi-dose glass vial containing 3.75 mL of elamipretide solution (elamipretide [80 mg/mL], phosphate buffer, and benzyl alcohol)
- Sponsor
- David Marcinek
- Ages
- 65 Years to 80 Years
- Dates
- First posted Dec 10, 2025 · updated Dec 10, 2025
Registry summary
This study will utilize a daily dose of elamipetide for 4 weeks and will screen a sufficient number of subjects for 30 subjects to enroll in the study. The planned duration of the study includes baseline measurement, followed by 4 weeks intervention period, a midpoint (2week ±3days) check-in phone interview, and post intervention visits that mirror the baseline visits. After the last injection, subjects will enter the 2-week follow-up period, concluded by the end-of-study contact.
Sites (1)
- University of Washington, Seattle, Washington, United States